Related references
Note: Only part of the references are listed.Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis
Raphael Szalat et al.
LEUKEMIA (2021)
Systemic amyloidosis from A (AA) to T (ATTR): a review
E. Muchtar et al.
JOURNAL OF INTERNAL MEDICINE (2021)
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
E. Kastritis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Conventional Therapy for Amyloid Light-Chain Amyloidosis
Paolo Milani et al.
ACTA HAEMATOLOGICA (2020)
Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment
Morie A. Gertz
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis
Shayna Sarosiek et al.
BLOOD CANCER JOURNAL (2020)
First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network
Giovanni Palladini et al.
BLOOD (2020)
Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database
Angela Dispenzieri et al.
BLOOD (2020)
Prognosis and Staging of AL Amyloidosis
Tobias Dittrich et al.
ACTA HAEMATOLOGICA (2020)
Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial
Monique C. Minnema et al.
HAEMATOLOGICA (2019)
Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement information system-global health (PROMIS-GH) in a real-world population
Rajshekhar Chakraborty et al.
LEUKEMIA & LYMPHOMA (2019)
General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States
S. Nolte et al.
EUROPEAN JOURNAL OF CANCER (2019)
Patient-reported distress is prevalent in systemic light chain (AL) amyloidosis but not determined by severity of disease
Nicholas L. Wright et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2018)
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
Maria Gavriatopoulou et al.
LEUKEMIA (2018)
Systemic immunoglobulin light chain amyloidosis
Giampaolo Merlini et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
The burden of amyloid light chain amyloidosis on health-related quality of life
Martha Bayliss et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples
Michelle K. White et al.
PATIENT-RELATED OUTCOME MEASURES (2017)
A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time
Vaishali Sanchorawala et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Vaishali Sanchorawala et al.
BLOOD (2017)
Hematology patient reported symptom screen to assess quality of life for AL amyloidosis
Rahma Warsame et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
Eli Muchtar et al.
BLOOD (2017)
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation
Anita D'Souza et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
Isabelle Lousada et al.
ADVANCES IN THERAPY (2015)
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis
Gregory P. Kaufman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
The patient's perspective on the symptom and everyday life impact of AL amyloidosis
Huamao Mark Lin et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2015)
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience
Vaishali Sanchorawala et al.
BLOOD (2015)
Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
N. Weber et al.
INTERNAL MEDICINE JOURNAL (2015)
Guidelines on the management of AL amyloidosis
Ashutosh D. Wechalekar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2014)
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)
Arnaud Jaccard et al.
HAEMATOLOGICA (2014)
Update on treatment of light chain amyloidosis
Shameem Mahmood et al.
HAEMATOLOGICA (2014)
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2013)
New Insights and Modern Treatment of AL Amyloidosis
Chakra P. Chaulagain et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis
Riccardo Caccialanza et al.
ANNALS OF HEMATOLOGY (2012)
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
Joseph R. Mikhael et al.
BLOOD (2012)
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
Christopher P. Venner et al.
BLOOD (2012)
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
R. L. Comenzo et al.
LEUKEMIA (2012)
Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma
Ann Kristin Kvam et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
M. Herdman et al.
QUALITY OF LIFE RESEARCH (2011)
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
A. Simon Pickard et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
Arnaud Jaccard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome
PN Mollee et al.
BONE MARROW TRANSPLANTATION (2004)
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
M Skinner et al.
ANNALS OF INTERNAL MEDICINE (2004)
Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
DC Seldin et al.
BLOOD (2004)
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
A Dispenzieri et al.
BLOOD (2004)
Share Paper
